A detailed history of Barclays PLC transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Barclays PLC holds 8,330 shares of RPTX stock, worth $10,995. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,330
Previous 8,330 -0.0%
Holding current value
$10,995
Previous $29,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$2.75 - $3.99 $21,450 - $31,122
7,800 Added 1471.7%
8,330 $29,000
Q4 2023

Feb 15, 2024

SELL
$3.22 - $11.79 $11,347 - $41,547
-3,524 Reduced 86.93%
530 $4,000
Q3 2023

Nov 07, 2023

BUY
$8.16 - $13.01 $5,263 - $8,391
645 Added 18.92%
4,054 $49,000
Q2 2023

Aug 03, 2023

BUY
$8.63 - $12.53 $29,419 - $42,714
3,409 New
3,409 $36,000
Q2 2022

Aug 12, 2022

SELL
$8.45 - $14.84 $650 - $1,142
-77 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$11.38 - $21.88 $876 - $1,684
77 New
77 $1,000

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $55.4M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.